August 2005
Gail Louw > Other Awards
This award was given to a reseracher under 35 years old for outstanding presentation at a connference.
June 2010
Gail Louw > Other Awards
This award is funded by the Fogarty Foundation and the NIH to Post-Doctoral researchers. Through this award I was able to attend Harvard School of Public Health, Boston, MA, USA as a visiting fellow to conduct research for 3 months.
May 2012
Gail Louw > Other Awards
This award, Funded by Bill and Melina Gates foundation is awarded to reserachers to assist in attending conferences.
January 2013
Gail Louw > Other Awards
This was a career development funding awarded to Visiting Post-doctoral fellows to conduct their research at the NIH, Bethesda, USA
January 2017
Gail Louw > Other Awards
This is a career development award from the Robert Bosch Stiftung to assist African Scientist in their research.
Full Member
Dr. Gail Louw
Membership since:
2018
Field of activity:
Other Memberships/Affiliations
SAWISE
Degrees:
2009
Doctorate
Medical and Health Sciences incl Neurosciences
2003
Undergraduate
Biological Systems and Organisms
2004
Master
Biological Systems and Organisms
Publications resulting from Research
• Rabia Johnson, Elizabeth M Streicher, Gail E Louw; Robin M Warren, Paul D Van Helden, Thomas C Victor. Mycobacterium: Molecular Biology; Chapter 5: Drug resistance in Mycobacterium Tuberculosis, 2005.
• GE Louw, RM Warren, PR Donald, MB Murray, M Bosman, PD Van Helden, DB Young, TC Victor. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int J Tuberc Lung Dis, 2006. 10(7): p. 802-7
• Rabia Johnson, Elizabeth M. Streicher, Gail E. Louw, Robin M. Warren, Paul D. van Helden, Thomas C. Victor. Drug Resistance in Mycobacterium tuberculosis. Curr. Issues Mol. Biol. 8: 97–112. 2006.
• Gail E. Louw, Robin M. Warren, Paul D. van Helden, Thomas C. Victor. Rv2629 191A/C nucleotide change is not associated with rifampicin resistance in Mycobacterium tuberculosis. Clin Chem Lab Med, 2009. 47(4): p. 500-1
• G.E. Louw; R. M. Warren, N.C. Gey van Pittius, C.R.E. McEvoy, P.D. van Helden; T.C. Victor. A Balancing Act: Efflux/Influx in Mycobacterial Drug Resistance. Antimicrob Agents Chemother, 2009. 53(8): p. 3181-9
• Louw GE, Warren RM, Gey van Pittius NC, Leon R, Jimenez A, Pando RH, McEvoy CR, Grobbelaar M, Murray M, van Helden PD, Victor TC. Rifampicin Reduces Susceptibility to Ofloxacin in Rifampicin Resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med. 2011 Jul 15;184(2):269-76.
• Black PA, Warren RM, Louw GE, van Helden PD, Victor TC, Kana BD. Energy metabolism and drug efflux in Mycobacterium tuberculosis. Antimicrobial agents and Chemother, 2014. May; 58 (5):2491-503
• Black PA, de Vos M, Louw GE, van der Merwe RG, Dippenaar A, Streicher EM, Abdallah AM, Sampson SL, Victor TC, Dolby T, Simpson JA, van Helden PD, Warren RM, Pain A. Whole genome sequencing reveals genomic heterogeneity and antibiotic purification in Mycobacterium tuberculosis isolates. BMC Genomics. 2015 Oct 24;16(1):857
• Pule, Caroline; Sampson, Samantha; Warren, Rob; Black, Philippa; Van Helden, Paul; Victor, Tommie; Louw, Gail. Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy. J Antimicrob Chemother. 2016 Jan;71(1):17-26. Epub 2015 Oct 15.
• Gail E Louw, Samantha L Sampson. Chapter 10: Implications of Chromosomal Mutations for Mycobacterial Drug Resistance Book: Drug resistance in Bacteria, Fungi, Malaria and cancer. Springer International Publishing Switzerland. 2017
• GE Louw, RM Warren, PR Donald, MB Murray, M Bosman, PD Van Helden, DB Young, TC Victor. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int J Tuberc Lung Dis, 2006. 10(7): p. 802-7
• Rabia Johnson, Elizabeth M. Streicher, Gail E. Louw, Robin M. Warren, Paul D. van Helden, Thomas C. Victor. Drug Resistance in Mycobacterium tuberculosis. Curr. Issues Mol. Biol. 8: 97–112. 2006.
• Gail E. Louw, Robin M. Warren, Paul D. van Helden, Thomas C. Victor. Rv2629 191A/C nucleotide change is not associated with rifampicin resistance in Mycobacterium tuberculosis. Clin Chem Lab Med, 2009. 47(4): p. 500-1
• G.E. Louw; R. M. Warren, N.C. Gey van Pittius, C.R.E. McEvoy, P.D. van Helden; T.C. Victor. A Balancing Act: Efflux/Influx in Mycobacterial Drug Resistance. Antimicrob Agents Chemother, 2009. 53(8): p. 3181-9
• Louw GE, Warren RM, Gey van Pittius NC, Leon R, Jimenez A, Pando RH, McEvoy CR, Grobbelaar M, Murray M, van Helden PD, Victor TC. Rifampicin Reduces Susceptibility to Ofloxacin in Rifampicin Resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med. 2011 Jul 15;184(2):269-76.
• Black PA, Warren RM, Louw GE, van Helden PD, Victor TC, Kana BD. Energy metabolism and drug efflux in Mycobacterium tuberculosis. Antimicrobial agents and Chemother, 2014. May; 58 (5):2491-503
• Black PA, de Vos M, Louw GE, van der Merwe RG, Dippenaar A, Streicher EM, Abdallah AM, Sampson SL, Victor TC, Dolby T, Simpson JA, van Helden PD, Warren RM, Pain A. Whole genome sequencing reveals genomic heterogeneity and antibiotic purification in Mycobacterium tuberculosis isolates. BMC Genomics. 2015 Oct 24;16(1):857
• Pule, Caroline; Sampson, Samantha; Warren, Rob; Black, Philippa; Van Helden, Paul; Victor, Tommie; Louw, Gail. Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy. J Antimicrob Chemother. 2016 Jan;71(1):17-26. Epub 2015 Oct 15.
• Gail E Louw, Samantha L Sampson. Chapter 10: Implications of Chromosomal Mutations for Mycobacterial Drug Resistance Book: Drug resistance in Bacteria, Fungi, Malaria and cancer. Springer International Publishing Switzerland. 2017
Gordon Research conference: Tuberculosis Drug discovery and development: Challenges, advances and future prospects in the fight against tuberculosis.
2025
Girona, Spain
Investigating the Sequential Development of Drug Resistance in Mycobacterium tuberculosis
American Society for Microbiology, 115th General Meeting
2025
New Orleans, LA, USA
Investigating the Sequential Development of Drug Resistance in Mycobacterium tuberculosis
Keystone conference on Drug Resistance and Persistence
2025
Kampla, Uganda
Mycobacterium tuberculosis sputum cultures show polyphenotypic rifampicin resistance.
8th International conference on the pathogenesis of mycobacterial infection
2025
Stockholm, Sweden
Rifampicin reduces susceptibility to Ofloxacin in Rifampicin Resistant Mycobacterium tuberculosis through efflux
ANNUAL ACADEMIC YEARDAY
2025
Cape Town, South Africa
Anti-tuberculosis drugs: When “heros” become “villains”
American Society for Microbiology, General meeting
2025
San Diego, CA, USA
Activated Efflux Pumps Define the Level of Rifampicin Resistance in Mycobacterium tuberculosis
MRC TB COLLOQUIUM
2025
Cape Town, South Africa
New Hope for the treatment of drug resistant Tuberculosis
KEYSTONE SYMPOSIUM (OVERCOMING THE CRISIS OF TB AND HIV)
2025
Arusha, Tanzania
New Hope for the treatment of drug resistant Tuberculosis
INFECTIOUS DISEASES SYMPOSIUM
2025
Cape Town, South Africa
Can rifampicin susceptibility be restored in drug- resistant clinical isolates of Mycobacterium tuberculosis?
38th Union World Conference on Lung Health
2025
Cape Town, South Africa
Efflux Pump Inhibitors modulate Rifampicin Resistance in Mycobacterium tuberculosis
48th ANNUAL ACADEMIC YEAR DAY
2025
Cape Town, South Africa
Pyrazinamide resistance: Frequency and the implications for the management of drug resistant Tuberculosis
SWISS/SA Bioinformatics Workshop: Databases and Metabolic modelling course.
2025
Cape Town, South Africa
SET Supervision Workshop
2025
Stellenbosch, South Africa
Design and Interpretation of Clinical trials (online)
2025
Johns Hopkins University, USA (Online)
Epidemiology: The Basic Science of Public Health (online)
2025
University of North Carolina (Online)
Epidemics – the Dynamics of Infectious diseases (online)
2025
Pennsylvania State University, USA (Online)
Global Tuberculosis Clinical Management and Research (online)
2025
John's Hopkins University, USA (Online)
Introduction to lab safety
2025
NIH, Bethesda, USA
Working Safely with HIV and other bloodborne pathogens for non-Hospital Personnel
2025
NIH, Bethesda, USA
Lab safety at NIH
2025
NIH, Bethesda, USA
Browsing genes and genomes with ENSEMBLE
2025
Harvard Medical School, Boston, USA
UCSC Genome Browser
2025
Harvard Medical School, Boston, USA
Blast Tips and Tricks
2025
Harvard Medical School, Boston, USA
XDR-TB conference 2017
2025
Cape Town, South Africa
Swiss/SA symposium in pathogen genomics
2025
Cape Town, South Africa
Gordon Research conference: Tuberculosis Drug discovery and development
2025
Girona, Spain
American Society for Microbiology, 115th General Meeting
2025
New Orleans, LA, USA
Keystone conference on Drug Resistance and Persistence
2025
Kampala, Uganda
8th International conference on the pathogenesis of mycobacterial infections
2025
Stockholm, Sweden
KEYSTONE SYMPOSIUM (OVERCOMING THE CRISIS OF TB AND HIV)
2025
Arusha, Tanzania